Autoantibody-mediated disorders of the central nervous system

References

• Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003; 2: 94–100
   PubMedGoogle Scholar
• Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997; 41: 238–246
   PubMed Web of Science ®Google Scholar
• Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: Subunit specificity correlates with clinical manifestations. Brain 2006; 129: 1570–1584
   PubMed Web of Science ®Google Scholar
• Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, van Kempen GT, Chauplannaz G, Wintzen AR, van Dijk JG, Newsom-Davis J. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995; 38: 701–702
   PubMedGoogle Scholar
• Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P. Morvan's syndrome: Peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124: 2417–2426
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Blackmore KJ, Fawcett PR, Birchall D, Vincent A, Barnard S, Walls TJ. Sub-acute presentation of Morvan's syndrome after thymectomy. J Neurol Neurosurg Psychiatry 2004; 75: 1504–1505
   PubMedGoogle Scholar
• Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120: 923–928
   PubMedGoogle Scholar
• Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701–712
   PubMed Web of Science ®Google Scholar
• Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62: 1177–1182
   PubMed Web of Science ®Google Scholar
• Coleman SK, Newcombe J, Pryke J, Dolly JO. Subunit composition of Kv1 channels in human CNS. J Neurochem 1999; 73: 849–858
   PubMedGoogle Scholar
• Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, Sonoda Y, Osame M, Kameyama M. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 2004; 56: 440–444
   PubMed Web of Science ®Google Scholar
• Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J. Treatment-responsive limbic encephalitis identified by neutropil antibodies: MRI and PET correlates. Brain 2005; 128: 1764–1777
   PubMed Web of Science ®Google Scholar
• Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: Immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007; 78: 381–385
   PubMed Web of Science ®Google Scholar
• Palace J, Lang B. Epilepsy: An autoimmune disease?. J Neurol Neurosurg Psychiatry 2000; 69: 711–714
   PubMed Web of Science ®Google Scholar
• Dedek K, Kunath B, Kananura C, Reuner U, Jentsch TJ, Steinlein OK. Myokymia and neonatal epilepsy by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc Natl Acad Sci USA 2001; 98: 12272–12277
   PubMed Web of Science ®Google Scholar
• McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S, Blank M, Shoenfeld Y, Vincent A, Palace J, Lang B. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65: 1730–1736
   PubMed Web of Science ®Google Scholar
• Majoie M, de Baets M, Renier W, Lang B, Vincent A. Antibodies to voltage-gated potassium channels in epilepsy. Epilepsy Res 2006; 71: 135–141
   PubMed Web of Science ®Google Scholar
• Costa M, Saiz A, Casamitjana R, Fernandez Castaner M, Sanmarti A, Graus F, Jaraquemada D. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clin Exp Immunol 2002; 129: 471–478
   PubMedGoogle Scholar
• Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 51–56
   Google Scholar
• Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555–1560
   PubMed Web of Science ®Google Scholar
• McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW. An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol 2006; 59: 204–206
   PubMedGoogle Scholar
• Kwan P, Sills GJ, Kelly K, Butler E, Brodie MJ. Glutamic acid decarboxylase in controlled and uncontrolled epilepsy: A pilot study. Epilepsy Res 2000; 41: 191–195
   PubMedGoogle Scholar
• Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998; 352: 457
   PubMed Web of Science ®Google Scholar
• Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keranen T, Graus F. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46–50
   PubMed Web of Science ®Google Scholar
• Honnorat J, Trouillas P, Thivolet C, Aguera M, Belin MF. Autoantibodies to glutamate decarboxylase in a patient with cerebellar cortical atrophy, peripheral neuropathy and slow eye movements. Arch Neurol 1995; 52: 462–468
   PubMedGoogle Scholar
• Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E, Graus F. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 1997; 49: 1026–1030
   PubMedGoogle Scholar
• Abele M, Weller M, Mescheriakov S, Burk K, Dichgans J, Klockgether T. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology 1999; 52: 857–859
   PubMed Web of Science ®Google Scholar
• Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, Mucignat C. Peculiar labeling of cultured hippocampal neurons by different sera harbouring anti-glutamic acid decarboxylase autoantibodies. Exp Neurol 2006; 202: 514–518
   PubMed Web of Science ®Google Scholar
• Mitoma H, Song S-Y, Ishida K, Yamakuni T, Kobayashi T, Mizusawa H. Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. J Neurol Sci 2000; 175: 40–44
   PubMed Web of Science ®Google Scholar
• Bartolomei F, Boucraut J, Barrie M, Kok J, Dravet C, Viallat D, Bernard D, Gastaut JL. Cryptogenic partial epilepsies with anti-GM1 antibodies: A new form of immune-mediated epilepsy?. Epilepsia 1996; 37: 922–926
   PubMedGoogle Scholar
• Karpiak SE, Graf L, Rapport MM. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976; 194: 735–737
   PubMed Web of Science ®Google Scholar
• Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648–651
   PubMed Web of Science ®Google Scholar
• Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A, Caraballo R. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994; 44: 1030–1036
   PubMed Web of Science ®Google Scholar
• Leach JP, Chadwick DW, Miles JB, Hart IK. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 1999; 52: 738–742
   PubMed Web of Science ®Google Scholar
• Twyman RE, Gahring LC, Spiess J, Rogers SW. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist-binding site. Neuron 1995; 14: 755–762
   PubMed Web of Science ®Google Scholar
• Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci 2000; 20: 7307–7316
   PubMedGoogle Scholar
• Wiendl H, Bien CG, Bernasconi P, Fleckenstein B, Elger CE, Dichgans J, Mantegazza R, Melms A. GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57: 1511–1514
   PubMed Web of Science ®Google Scholar
• Watson R, Jiang Y, Bermudez I, Houlihan L, Clover L, McKnight K, Cross JH, Hart IK, Roubertie A, Valmier J, Hart Y, Palace J, Beeson D, Vincent A, Lang B. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004; 63: 43–50
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Laxer K, Saketkhoo R, Elkins MK, Parent JM, Mantegazza R, Oksenberg JR. Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis. Neurology 2002; 58: 709–716
   PubMed Web of Science ®Google Scholar
• Yang R, Puranam RS, Butler LS, Qian WH, He XP, Moyer MB, Blackburn K, Andrews PI, McNamara JO. Autoimmunity to munc-18 in Rasmussen's encephalitis. Neuron 2000; 28: 375–383
   PubMed Web of Science ®Google Scholar
• Watson R, Jepson JE, Bermudez I, Alexander S, Hart Y, McKnight K, Roubertie A, Fecto F, Valmier J, Sattelle DB, Beeson D, Vincent A, Lang B. Alpha7-acetylcholine receptor antibodies in two patients with Rasmussen encephalitis. Neurology 2005; 65: 1802–1804
   PubMedGoogle Scholar
• Gahring LC, Carlson NG, Rogers SW. Antibodies prepared to neuronal glutamate receptor subunit 3 bind IFN alpha-receptors: Implications for an autoimmune process. Autoimmunity 1998; 28: 243–248
   PubMed Web of Science ®Google Scholar
• Bauer J, Bien CG, Lassmann H. Rasmussen's encephalitis: A role for autoimmune cytotoxic T lymphocytes. Curr Opin Neurol 2002; 15: 197–200
   PubMed Web of Science ®Google Scholar
• Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: Distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res 2005; 65: 11–22
   PubMed Web of Science ®Google Scholar
• DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189–1193
   PubMed Web of Science ®Google Scholar
• Kowal C, DeGiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B. Human lupus autoantibodies against MNDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006; 103: 19854–19859
   PubMed Web of Science ®Google Scholar
• Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: Antibodies alter emotion. Proc Natl Acad Sci USA 2006; 103: 678–683
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Mori H, Mishina M, Watanabe M, Kondo N, Shimomura J, Kubota Y, Matsuda K, Fukushima K, Shiroma N, Akasaka N, Nishida H, Imamura A, Watanabe H, Sugiyama N, Ikezawa M, Fujiwara T. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluR epsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia 2005; 6: 152–158
   Google Scholar
• Mochizuki Y, Mizutani T, Isozaki E, Ohtake T, Takahashi Y. Acute limbic encephalitis: A new entity?. Neurosci Lett 2006; 394: 5–8
   PubMedGoogle Scholar
• Lang B, Newsom Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol (Lond) 1983; 344: 33545
   Google Scholar
• Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q-type calcium channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59: 764–766
   PubMed Web of Science ®Google Scholar
• Mason WP, Graus F, Lang B, Honnorat J, Delatrre J-Y, Vallderiola F, Antoine C, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Paraneoplastic cerebellar degeneration and small-cell carcinoma. Brain 1998; 120: 1279–1300
   Google Scholar
• Pinto A, Gillard S, Moss F, Whyte K, Burst P, Williams M, Stauderman K, Harpold M, Lang B, Newsom-Davis, Bleakman D, Lodge D, Boot J. Human autoantibodies specific for α1A calcium channel subunit reduce both P-type and Q-type calcium channels in cerebellar neurons. Proc Natl Acad Sci USA 1998; 95: 8328–8333
   PubMedGoogle Scholar
• Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker SJ, Snutch TP, Lennon VA. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clinic Proc 1992; 67: 1150–1159
   PubMedGoogle Scholar
• Jun K, Piedras-Renteria ES, Smith SM, Wheeler DB, Lee SB, Lee TG, Chin H, Adams ME, Scheller RH, Tsien RW, Shin HS. Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci USA 1999; 96: 15245–15250
   PubMed Web of Science ®Google Scholar
• Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, Tsujihata M, Eguchi K. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert–Eaton myasthenic syndrome. Ann Neurol 2003; 53: 21–28
   PubMed Web of Science ®Google Scholar
• Hadjivassiliou M, Boscolo S, Davies-Jones GAB, Grunewald RA, Not T, Sanders DS, Simpson JE, Tongiorgi E, Williamson CA, Woodroofe NM. The humoral response in the pathogenesis of gluten ataxia. Neurology 2002; 58: 1221–1226
   PubMed Web of Science ®Google Scholar
• Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallet M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001; 49: 540–543
   PubMed Web of Science ®Google Scholar
• Chen D-H, Brkanac Z, Verlinda C, Tan X-J, Bylenok L, Nochlin D, Matsushita M, Lipe H, Wolff J, Fernandez M, Cimino P, Bird T, Raskind W. Missense mutations in the regulatory domain of PKC? A novel mechanism for dominant cerebellar ataxia. Am J Hum Gen 2003; 72: 839–849
   PubMedGoogle Scholar
• Kinoshita A, de Leeuw B, Moll W, Coesmans M, Jaarsma D, Henzen-Logmans S, Vecht C, De Zeeuw C, Sekiyama N, Nakanishi S, Shigemoto R. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342: 21–27
   PubMedGoogle Scholar
• Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964–968
   PubMed Web of Science ®Google Scholar
• Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579–582
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450–1461
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473–477
   PubMed Web of Science ®Google Scholar
• Snider LA, Swedo SE. Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol 2003; 16: 359–365
   PubMed Web of Science ®Google Scholar
• Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nature Med 2003; 9: 914–920
   PubMed Web of Science ®Google Scholar
• Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovannonni G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006; 172: 187–197
   PubMed Web of Science ®Google Scholar
• Singer HS, Hong JJ, Yoon DY, Williams PN. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology 2005; 65: 1701–1707
   PubMed Web of Science ®Google Scholar
• Hallet JJ, Harling-Berg CJ, Knopf PM, Stopa EG, Kiessling LS. Anti-striatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 2000; 111: 195–202
   PubMedGoogle Scholar
• Loiselle CR, Lee O, Moran TH, Singer HS. Striatal microinfusion of Tourette syndrome and PANDAS sera: Failure to induce behavioural changes. Mov Disorders 2004; 19: 390–396
   PubMed Web of Science ®Google Scholar
• Wilson J. Neuroimmunology of dancing eye syndrome in children. Dev Med Child Neurol 2006; 48: 693–696
   PubMedGoogle Scholar
• Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro MA, Parke JT, Stumpf DA, Verhulst SJ. B- and T-cell markers in opsoclonus–myoclonus syndrome: Immunophenotyping of CSF lymphocytes. Neurology 2004; 62: 1526–1532
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus–myoclonus syndrome: A biomarker of disease activity. Mov Disord 2004; 19: 770–777
   PubMed Web of Science ®Google Scholar
• Connolly AM, Pestronk A, Mehta S, Pranzatelli MR, Noetzel MJ. Serum autoantibodies in childhood opsoclonus–myoclonus syndrome: An analysis of antigenic targets in neural tissues. J Pediatr 1997; 30: 878–884
   Google Scholar
• Korfei M, Fuhlhuber V, Schmidt-Woll T, Kaps M, Preissner KT, Blaes F. Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus-syndrome. J Neuroimmunol 2005; 170: 150–157
   PubMed Web of Science ®Google Scholar
• Blaes F, Fuhlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, Kaps M, Preissner KT. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58: 313–317
   PubMed Web of Science ®Google Scholar
• Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Carter J, Sirven J, Hunder G, Fatourechi V, Mokri B, Drubach D, Pittock S, Lennon V, Boeve B. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63(2)197–202
   PubMedGoogle Scholar
• Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: Syndrome or myth?. Arch Neurol 2003; 60: 164–171
   PubMedGoogle Scholar
• Oide T, Tokuda T, Yazaki M, Watarai M, Mitsuhashi S, Kaneko K, Hashimoto T, Ohara S, Ikeda S. Anti-neuronal autoantibody in Hashimoto's encephalopathy: Neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004; 217: 7–12
   PubMedGoogle Scholar
• Ochi H, Horiuchi I, Araki N, Toda T, Araki T, Sato K, Murai H, Osoegawa M, Yamada T, Okamura K. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto's encephalopathy. FEBS Lett 2002; 528: 197–202
   PubMed Web of Science ®Google Scholar
• McCabe DJ, Burke T, Connolly S, Hutchinson M. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy. Neurology 2000; 54: 737–739
   PubMedGoogle Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543–1554
   PubMed Web of Science ®Google Scholar
• Madrid A, Gil-Peralta A, Gil-Neciga E, Gonzalez JR, Jarrin S. Morvan's fibrillary chorea: Remission after plasmapheresis. J Neurol 1996; 243: 350–353
   PubMedGoogle Scholar
• Karpiak SE, Mahadik SP, Graf L, Rapport MM. An immunological model of epilepsy: Seizures induced by antibodies to GM1 ganglioside. Epilepsia 1981; 22: 89–196
   Google Scholar
• Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470–475
   PubMed Web of Science ®Google Scholar